Is Theravance Biopharma Stock a Good Investment?
Theravance Biopharma Investment Advice | TBPH |
- Examine Theravance Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Theravance Biopharma's leadership team and their track record. Good management can help Theravance Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Theravance Biopharma's business and its evolving consumer preferences.
- Compare Theravance Biopharma's performance and market position to its competitors. Analyze how Theravance Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Theravance Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Theravance Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Theravance Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Theravance Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Theravance Biopharma Stock
Researching Theravance Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of Theravance Biopharma was at this time reported as 4.43. The company recorded a loss per share of 1.0. Theravance Biopharma had not issued any dividends in recent years.
To determine if Theravance Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Theravance Biopharma's research are outlined below:
| Theravance Biopharma generated a negative expected return over the last 90 days | |
| Theravance Biopharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 57.42 M. Net Loss for the year was (55.19 M) with loss before overhead, payroll, taxes, and interest of (12.05 M). | |
| Theravance Biopharma currently holds about 132.85 M in cash with (27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Theravance Biopharma has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors |
Theravance Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Theravance Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Theravance Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Theravance Biopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 445.3 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Theravance Biopharma's market, we take the total number of its shares issued and multiply it by Theravance Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Theravance Biopharma's profitablity analysis
Theravance Biopharma's profitability indicators refer to fundamental financial ratios that showcase Theravance Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Theravance Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Theravance Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Theravance Biopharma's profitability requires more research than a typical breakdown of Theravance Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.96) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.36) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.36. Determining Theravance Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Theravance Biopharma is a good buy. For example, gross profit margin measures Theravance Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Theravance Biopharma's profitability and make more informed investment decisions.
The data published in Theravance Biopharma's official financial statements usually reflect Theravance Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Theravance Biopharma. For example, before you start analyzing numbers published by Theravance accountants, it's critical to develop an understanding of what Theravance Biopharma's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Theravance Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Theravance Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Theravance Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Theravance Biopharma. Please utilize our Beneish M Score to check the likelihood of Theravance Biopharma's management manipulating its earnings.
Basic technical analysis of Theravance Stock
As of the 27th of April, Theravance Biopharma has the Variance of 6.04, coefficient of variation of (2,069), and Risk Adjusted Performance of (0.02). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Theravance Biopharma, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Theravance Biopharma, which can be compared to its competition. Please validate Theravance Biopharma coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and skewness to decide if Theravance Biopharma is priced more or less accurately, providing market reflects its prevalent price of 9.12 per share. Given that Theravance Biopharma has information ratio of (0.08), we advise you to double-check Theravance Biopharma's current market performance to make sure the company can sustain itself at a future point.Theravance Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theravance Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theravance Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theravance Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Theravance Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Theravance Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 1.27 | |||
| Mean Deviation | 1.87 | |||
| Coefficient Of Variation | (2,069) | |||
| Standard Deviation | 2.46 | |||
| Variance | 6.04 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.44) | |||
| Treynor Ratio | 1.26 | |||
| Maximum Drawdown | 11.38 | |||
| Value At Risk | (3.60) | |||
| Potential Upside | 3.46 | |||
| Skewness | 0.2743 | |||
| Kurtosis | 0.8487 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 1.27 | |||
| Mean Deviation | 1.87 | |||
| Coefficient Of Variation | (2,069) | |||
| Standard Deviation | 2.46 | |||
| Variance | 6.04 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.44) | |||
| Treynor Ratio | 1.26 | |||
| Maximum Drawdown | 11.38 | |||
| Value At Risk | (3.60) | |||
| Potential Upside | 3.46 | |||
| Skewness | 0.2743 | |||
| Kurtosis | 0.8487 |
Consider Theravance Biopharma's intraday indicators
Theravance Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Theravance Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Theravance Biopharma time-series forecasting models is one of many Theravance Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Theravance Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Theravance Stock media impact
Far too much social signal, news, headlines, and media speculation about Theravance Biopharma that are available to investors today. That information is available publicly through Theravance media outlets and privately through word of mouth or via Theravance internal channels. However, regardless of the origin, that massive amount of Theravance data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Theravance Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Theravance Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Theravance Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Theravance Biopharma alpha.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Theravance Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Theravance Biopharma Corporate Directors
Theravance Biopharma corporate directors refer to members of a Theravance Biopharma board of directors. The board of directors generally takes responsibility for the Theravance Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Theravance Biopharma's board members must vote for the resolution. The Theravance Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| William Young | Director | Profile | |
| Donal OConnor | Independent Director | Profile | |
| George Whitesides | Director | Profile | |
| Laurie Alsup | Independent Director | Profile |
How to buy Theravance Stock?
To provide specific investment advice or recommendations on Theravance Biopharma stock, we recommend investors consider the following general factors when evaluating Theravance Biopharma. This will help you to make an informed decision on whether to include Theravance Biopharma in one of your diversified portfolios:- Examine Theravance Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Theravance Biopharma's leadership team and their track record. Good management can help Theravance Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Theravance Biopharma's business and its evolving consumer preferences.
- Compare Theravance Biopharma's performance and market position to its competitors. Analyze how Theravance Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Theravance Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Theravance Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Theravance Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Theravance Biopharma is a good investment.
Already Invested in Theravance Biopharma?
The danger of trading Theravance Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Theravance Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Theravance Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Theravance Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Theravance Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.